Kodiak Sciences Inc., was incorporated as a limited liability company on June 22, 2009 under the name of Oligasis LLC. On September 8, 2015, it changed its name and incorporated in Delaware. The company is a clinical-stage biopharmaceutical company specializing in novel therapies for the treatment of chronic hyperepidemic retinal diseases. Kodiak Sciences Inc .'s most advanced product candidate is KSI-301, a biological therapy built using the company's antibody biopolymer coupling platform (ABC Platform) to maintain potent and potent drug levels in ocular tissue. 

Expected P&L on Expiry

Key Stats

Pricing Model

About KOD20260618C35